AIM ImmunoTech Inc. announced the granting of U.S. patent No. 12312376, titled "Therapeutic Double Stranded RNA and Methods for Producing the Same." The patent, which expires on January 25, 2041, covers methods for manufacturing therapeutic double-stranded RNA products, including Ampligen®. This new patent enhances AIM's intellectual property portfolio, providing extended patent protection for manufacturing Ampligen until 2041. The protection supports AIM's ongoing development efforts for Ampligen as it seeks FDA approval for various medical indications, including cancers, viral diseases, and immune system disorders. AIM's CEO, Thomas K. Equels, highlighted the patent as a significant milestone in securing the company's global patent portfolio for Ampligen.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.